Pargluva Panic: Need For Additional Trial Prompts Merck To Drop Partnership

Bristol-Myers Squibb remains in discussions with FDA about what clinical studies would be required to address concerns about the cardiovascular safety profile of its type 2 diabetes treatment candidate Pargluva (muraglitazar)